AstraZeneca to take $140M hit for another R&D failure

Embattled AstraZeneca just can't catch a break. The pharma giant ($AZN) scrapped its development plans for the rheumatoid arthritis treatment fostamatinib, planning to take a $140 million write-off on the investment. It's just the latest in a series of development failures for AstraZeneca, which needs new revenue to make up for multibillion-dollar patent losses. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.